Real-world experience with eculizumab in Japanese patients with myasthenia gravis: Post-marketing surveillance data

被引：0
|
作者：
Takahashi, M. [1 ]
Masuda, M. [2 ]
Watanabe, M. [3 ]
Fukamizu, Y. [4 ]
Osawa, T. [4 ]
Kikui, H. [4 ]
Murai, H. [5 ]
机构：
[1] Osaka Univ, Dept Neurol, Grad Sch Med, Osaka, Japan
[2] Tokyo Med Univ, Dept Neurol, Tokyo, Japan
[3] Kyushu Univ, Neurol Inst, Grad Sch Med Sci, Dept Neurol, Fukuoka, Japan
[4] Alex Pharma GK, AstraZeneca Rare Dis, Tokyo, Japan
[5] Int Univ Hlth & Welf, Dept Neurol, Narita, Japan
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-396
引用
收藏
页码：574 / 574
页数：1
相关论文
共 50 条
  • [31] Real-World Evidence of an Emollient Device for Atopic and Contact Dermatitis in Pediatric to Adult Patients - Data from a Post-Marketing Surveillance
    Hebert, Adelaide Ann
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 : 1797 - 1803
  • [32] Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
    Nakamura, S.
    Asano, T.
    Tanaka, Y.
    Sugimoto, K.
    Yoshigoe, S.
    Suzuki, Y.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I439 - I441
  • [33] Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data
    Yang, Hui
    Ding, Zhexin
    An, Zhuoling
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (03) : 333 - 338
  • [34] Post-Marketing Safety Surveillance of Vaccines in Japan for Older Adults: A Feasibility Assessment of Real-World Data Capabilities
    Zhou, Cindy Ke
    Yasui, Daisaku
    Yoshinaga, Eiko
    Pearce, Kristina
    Martin, David
    Esposito, Daina B.
    Kubo, Tadamichi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 274 - 275
  • [35] Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data
    Ni, Ming
    Yin, Xue-Dong
    Hu, Wen-Juan
    Zeng, Na
    Zhao, Bin
    Li, Zhi-Ling
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] REAL-WORLD EXPERIENCE WITH INDIVIDUALIZED DOSING OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Silvestri, Nicholas
    MUSCLE & NERVE, 2024, 70 (03) : 638 - 638
  • [37] A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data
    Zhou, Jie
    Ye, Junchang
    Chen, Maohua
    Zheng, Xinlei
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [38] A REAL-WORLD EXPERIENCE WITH EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS IN CHINA
    Chen, Yuping
    Wang, Yan
    Tao, Xiaoyong
    Yang, Yanhua
    Xu, Shengjie
    Qiu, Feng
    MUSCLE & NERVE, 2024, 70 (03) : 520 - 520
  • [39] REAL-WORLD DATA FROM PATIENTS WITH SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION: AN ANALYSIS OF ANTITHROMBIN SUPPLEMENTATION POST-MARKETING SURVEILLANCE DATA
    Eguchi, Yutaka
    SHOCK, 2024, 62 (01): : 38 - 39
  • [40] Safety and Efficacy of Real-World Use of Everolimus for Kidney Transplant Patients: Post-Marketing Surveillance in Japan.
    Harada, H.
    Watarai, Y.
    Uchida, J.
    Kamisawa, O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 675 - 675
12345